Rocket Pharmaceuticals Inc to Host In-Person Investor and Analyst Event Transcript - Thomson StreetEvents

Rocket Pharmaceuticals Inc to Host In-Person Investor and Analyst Event Transcript

Rocket Pharmaceuticals Inc to Host In-Person Investor and Analyst Event Transcript - Thomson StreetEvents
Rocket Pharmaceuticals Inc to Host In-Person Investor and Analyst Event Transcript
Published Dec 14, 2021
13 pages (8867 words) — Published Dec 14, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of RCKT.OQ corporate analyst meeting

  
Brief Excerpt:

...Mayur Kasetty My name is Mayur Kasetty. I'm Director of Business Development and Operations and Investor Relations Lead at Rocket Pharmaceuticals. Today, we are going to be discussing key updates from our ongoing clinical trials in three of our lentiviral programs, namely our registrational trial of RP-L102 in Fanconi Anemia, our Phase I trial of RP-L301 in Pyruvate Kinase Deficiency and our registrational trial of RP-L301 (sic) [RP-L201] in Leukocyte Adhesion Deficiency-I. Updates from each of these trials were presented at various sessions during this year's American Society of Hematology Conference, and we would like to recap these updates and address any questions. I am required to note this is not an official program of the ASH Annual Meeting. Before we begin, I would like to briefly discuss the use of forward-looking statements during this presentation. Statements that we make may include statements which are not historical facts and are considered forward-looking within the meaning...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Rocket Pharmaceuticals Inc
Ticker
RCKT.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Greg Harrison from Bank of America. When it comes to the PKD program, how should we be thinking about enrollment at this point now that you've had two of the adults with a fair amount of follow-up? How fast can you progress into the younger populations?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Great. And then just one follow-up on the other two programs. Where are you at with patient identification as you get closer to a potential approval? And what can be done to improve diagnosis and identification of those patients?

Table Of Contents

Rocket Pharmaceuticals Inc, Decibel Therapeutics Inc and Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference- Panel Transcript – 2022-09-07 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 7-Sep-22 3:20pm GMT

Rocket Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript – 2022-05-24 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 24-May-22 11:45am GMT

Rocket Pharmaceuticals Inc at Needham Healthcare Conference Transcript – 2022-04-11 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 11-Apr-22 2:15pm GMT

Rocket Pharmaceuticals Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript – 2022-04-01 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 1-Apr-22 12:00pm GMT

Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-10 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 10-Jan-22 6:30pm GMT

Rocket Pharmaceuticals Inc Danon Update Call Transcript – 2021-11-15 – US$ 54.00 – Edited Transcript of RCKT.OQ conference call or presentation 15-Nov-21 1:30pm GMT

Rocket Pharmaceuticals Inc Q2 2021 Earnings Call Transcript – 2021-08-09 – US$ 54.00 – Edited Transcript of RCKT.OQ earnings conference call or presentation 9-Aug-21 8:30pm GMT

Rocket Pharmaceuticals Inc to Discuss Danon Program Call Transcript – 2021-05-10 – US$ 54.00 – Edited Transcript of RCKT.OQ conference call or presentation 10-May-21 8:30pm GMT

Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-11 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 11-Jan-21 7:50pm GMT

Rocket Pharmaceuticals, Inc. - Special Call Transcript – 2020-12-08 – US$ 54.00 – Edited Transcript of RCKT.OQ conference call or presentation 8-Dec-20 9:15pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Rocket Pharmaceuticals Inc to Host In-Person Investor and Analyst Event Transcript" Dec 14, 2021. Alacra Store. May 16, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Rocket-Pharmaceuticals-Inc-to-Host-In-Person-Investor-and-Analyst-Event-T15068938>
  
APA:
Thomson StreetEvents. (2021). Rocket Pharmaceuticals Inc to Host In-Person Investor and Analyst Event Transcript Dec 14, 2021. New York, NY: Alacra Store. Retrieved May 16, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Rocket-Pharmaceuticals-Inc-to-Host-In-Person-Investor-and-Analyst-Event-T15068938>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.